. 2009 Oct 15;35(1):3–8. doi: 10.1007/s00264-009-0886-y

Table 3.

Meta-analysis results

Outcomes	Number of studies	Number of participants (n)		Test of homogeneity		RR (95% CI)	P value
Outcomes	Number of studies	S-COX-2	NS-COX	I²(%)	P value	RR (95% CI)	P value
Overall incidence of HO	4	113/367	122/369	64.5	0.04	1.0 (0.80, 1.24)^a	0.98^a
Overall incidence of HO				64.0	0.04	1.08 (0.71, 1.64)^b	0.73^b
Incidence of moderate severe HO ( Brooker II and III)	4	22/367	28/369	27.0	0.25	0.83 (0.48, 1.42)^a	0.49^a
Incidence of Brooker I	4	90/367	94/369	55.4	0.08	1.02 (0.79, 1.32)^a	0.89^a
Incidence of Brooker I				54.5	0.09	1.08 (0.69, 1.68)^b	0.74^b
Incidence of Brooker II	3	13/250	10/246	0.0	0.38	1.32 (0.59, 2.96)^a	0.50^a
Incidence of Brooker III	3	3/250	2/246	30.6	0.23	1.43 (0.29, 7.13)^a	0.66^a
Incidence of Brooker IV	4	1/367	0/369	NA	NA	3.19 (0.13, 76.36)^a	0.47^a

HO heterotopic ossification, S-COX-2 selective COX-2 inhibitor, NS-COX nonselective COX inhibitor, NA not available

^a Fixed-effect model

^b Random-effects model